Sara M Tolaney, MD, MPH, is an Assistant Professor of Medicine at Harvard Medical School and Associate Director for the Susan F Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women's Cancer Center. She received her medical degree from the University of California, San Francisco (UCSF), and completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in Hematology and Medical Oncology at Dana-Farber Cancer Institute. She also earned her master's degree in public health from Harvard School of Public Health. Her research focuses on the development of novel therapies in the treatment of breast cancer. Dr Tolaney is Principal Investigator (PI) of many therapeutic clinical trials and translational studies for breast cancer. She serves as Breast Cancer Leader for the Early Drug Development Center (EDDC) and Center for Immuno-Oncology (CIO) at Dana-Farber Cancer Institute. Dr Tolaney has developed many novel immunotherapy combination trials, many of which are currently ongoing. She serves on the Scientific Review Committee at Dana-Farber Cancer Institute and Leader of the ASCO Metastatic Breast Track Scientific Review Committee. She is the recipient of the Lee M Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.